Current Issue : April - June Volume : 2018 Issue Number : 2 Articles : 6 Articles
Since its approval by the US Food and Drug Administration in 2002 for glabellar wrinkles,\nbotulinum toxin (BTX) has been widely used to correct facial wrinkles. As a result, many consider\nBTX synonymous with cosmetic dermatology. Recent studies indicate that BTX elicits biological\neffects on various skin cell types via the modulation of neurotransmitter release, and it seems that BTX\nhas a wider zone of dermatologic influence than originally understood. Clinicians and researchers\nare now beginning to explore the potential of BTX beyond the amelioration of facial lines and\nencouraging results are seen with BTX in a variety of skin conditions. In this paper, we review novel\ndermatological indications of BTX which includes (but not limited to) scar prevention, facial flushing,\npost-herpetic neuralgia and itch. These areas show great promise, but there is definite need for\nlarger, double-blinded, randomized control trials against established treatments before BTX becomes\na clinical reality....
Background. Systemic sclerosis (SSc) and localized scleroderma (LoS) are two different diseases that may share some features.We\nevaluated the relationship between SSc and LoS in our case series of SSc patients. Methods. We analysed the clinical records of\n330 SSc patients, in order to find the eventual occurrence of both the two diseases. Results. Eight (2.4%) female patients presented\nboth the two diagnoses in their clinical histories. Six developed LoS prior to SSc; in 4/6 cases, the presence of autoantibodies\nwas observed before SSc diagnosis. Overall, the median time interval between LoS and SSc diagnosis was 18 (range 0ââ?¬â??156)\nmonths. Conclusions. LoS and SSc are two distinct clinical entities that may coexist.Moreover, as anecdotally reported in pediatric\npopulations, we suggested the possible development of SSc in adult patients with LoS, particularly in presence of Raynaudââ?¬â?¢s\nphenomenon or antinuclear antibodies before the SSc onset....
Fusarium spp. represent 9 to 44% of onychomycoses caused by fungi other than dermatophytes. This retrospective study describes\n17 cases of Fusarium onychomycosis diagnosed at the Laboratory of Parasitology and Mycology of Le Dantec University Hospital\nin Dakar, Senegal, from 2014 to 2016. It included all patients received in the laboratory for suspicion of onychomycosis between\nJanuary 1, 2014, andDecember 31, 2016. Diagnosis was based onmycological examination including direct examination and culture.\nMycological analysis was considered positive when direct examination and culture were positive after at least one repeat. Seventeen\nFusarium onychomycosis cases representing 12.9% of all onychomycoses reported were diagnosed. There were 5 cases on the\nfingernails and 12 on the toenails in 6 males and 11 females, and the mean age was 44 years (range: 26ââ?¬â??64). Onychomycoses were\ndiagnosed in immunocompetent patients except in a diabetic patient. The mean duration of lesions was 4.9 years (range: 1ââ?¬â??15),\nand distal subungual onychomycosis was predominant. Almost all patients were from suburban areas of Dakar region. The most\nfrequent species isolated belong to Fusariumsolani complex. Because of the risk of disseminated infection in immunocompromised\npatients, realization of susceptibility tests is necessary to ensure better therapeutic management....
Onychophagia, which refers to compulsive nail-biting behavior, is common among children and young adults. Onychophagia\ncan cause destruction to the cuticle and nail plate, leading to shortening of nails, chronic paronychia, and secondary infections.\nRelatively uncommon effects include pigmentary changes, such as longitudinal melanonychia and splinter hemorrhages.We report\na case of a young adult with longitudinal melanonychia, splinter hemorrhages, punctate leukonychia, and pterygium inversum\nunguis, concurrently induced by onychophagia. Importantly, patients usually do not report this behavior when asked about\nnail-related changes. Even upon questioning, they may deny nail-biting behavior. As in many other dermatological disorders,\ndermoscopy can be helpful in the diagnosis of nail disorders....
Objective. This study aimed to determine the prevalence of and factors associated with self-medication in dermatology in LomÃ?´e,\nTogo. Methods. We conducted an analytical cross-sectional study from February to April 2016 in 2 dermatology departments in\nLomÃ?´e. Univariate and multivariate logistic regression models were carried out to identify possible factors associated with selfmedication.\nResults. A total of 711 patients were included in the study. The mean age (Ã?±SD) of the patients was 26.6 Ã?± 6.9 years\nand the sex ratio (male/female) was 0.6. The main dermatologic diseases recorded were immunoallergic dermatoses (39.7%) and\ninfectious skin diseases (22.6%). Two-thirds (481/711; 66.7%) of the patients had practiced self-medication before consultation in\ndermatology units. In multivariate analysis, factors associated with self-medication were female sex (aOR = 1.44; 95% CI = [1.01,\n2.05]), duration of dermatologic disease more than one year (aOR = 1.79; IC = [1.19, 2.68]), adnexal dermatoses (aOR = 2.31; 95% IC\n= [1.03ââ?¬â??5.21]), keratinization disorders (aOR = 4.23; 95% CI = [1.36ââ?¬â??13.13]), and fungal skin infections (aOR = 5.43; 95% CI = [2.20,\n13.38]). Conclusion. Our study confirms that self-medication practice is very common among patients with dermatologic diseases\nin LomÃ?´e and has identified associated factors....
Diagnosis and treatment of Langerhans cell histiocytosis (LCH) in elderly patients are often difficult.We report here a 61-year-old\nfemale suffering froma refractory axillary ulcer for nearly a year, whose biopsy revealed LCH. It was also noted that the patient had\nother cutaneous papulovesicular eruptions of LCH as well as central diabetes insipidus. The patient was first successfully treated\nwith multiagent chemotherapy (cytosine arabinoside/vinblastine/prednisolone). DDAVP also well controlled diabetes insipidus;\nhowever, the axillary ulcer and cutaneous LCH relapsed. Thereafter, we found topical imiquimod to be effective in the treatment of\nrelapsed cutaneous LCH lesions....
Loading....